公开(公告)号：US20250034641A1

公开(公告)日：2025-01-30

申请号：US18914680

申请日：2024-10-14

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Aymeric DUCLERT ,  Mathieu SIMON ,  Philippe DUCHATEAU ,  Alan Marc WILLIAMS ,  Laurent POIROT

IPC: C12Q1/6881 ,  A61K39/00

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US20220233588A1

公开(公告)日：2022-07-28

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Aymeric DUCLERT ,  Mathieu SIMON ,  Philippe DUCHATEAU ,  Alan Marc WILLIAMS ,  Laurent POIROT

IPC: A61K35/17 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US20210017545A1

公开(公告)日：2021-01-21

申请号：US17041359

申请日：2019-03-29

Applicant: CELLECTIS

Inventor： Alex BOYNE ,  Brian BUSSER ,  Philippe DUCHATEAU ,  Aymeric DUCLERT

IPC: C12N15/90 ,  C12N15/86 ,  C07K14/805 ,  C12N15/10 ,  C12N9/22

Abstract: The present invention relates to the field of genome engineering (gene editing). More specifically the invention provides with allele specific TALE-nucleases and methods to operate allele specific gene repair by homologous recombination in primary cells, such as hematopoietic stem cells, blood cells and hepatocytes. These reagents and methods can be used for the genetic treatment of inherited disease, such as sickle cell disease betathalassemia.